Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Dividend Investing
5 ASX 200 shares that boosted their dividends this reporting season
Dividend Investing
Passive income watch: The ASX shares delivering the biggest dividend boosts this earnings season so far
Earnings Results
5 figures from ASX shares that impressed this week in reporting season
Best Shares
Here are the top 10 ASX 200 shares today
Share Market News
Here are the top 10 ASX 200 shares today
Share Gainers
Why Cochlear, CSL, Life360, and Pro Medicus shares are racing higher
Earnings Results
Cochlear share price lifts on 21% dividend boost
Blue Chip Shares
Analysts say these 4 ASX blue chip shares are buys
Share Market News
Returning capital: These ASX companies have been buying back their shares in 2023
Broker Notes
Analysts say these ASX 100 shares are buys right now
Blue Chip Shares
Analysts say these ASX 200 stocks are quality buys for FY24
Broker Notes
These high quality ASX 200 shares could be buys in July
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
